Treatment Information

Back

Prostate Cancer treatment details. Chemotherapy, Biologic therapy.

Cedars-Sinai Medical Center, Los Angeles, CA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Los Angeles, CA
Treatments:Chemotherapy, Biologic therapyHospital:Cedars-Sinai Medical Center
Drugs:Journal:Link
Date:Jul 2007

Description:

Patients: This phase II study involved 22 elderly patients with androgen-independent, progressive prostate cancer. The median age was 73.5 years, ranging from 65 to 80.

Treatment: These men were treated with the chemotherapy drug docetaxel and the biologic therapy erlotinib.

Toxicity: Grade 3/4 toxicities included anemia (in 1 patient), neutropenia (in 9 patients), and 2 cases of febrile neutropenia. Other toxicities included rash, fatigue, taste alteration, nausea, mucositis, and diarrhea. These were mostly grade 1 and 2.

Results: The median overall survival was 24.6 months. The authors concluded that this study suggests that the overall survival in patients treated with docetaxel and erlotinib is similar to those treated with just docetaxel.

Correspondence: Dr. Mitchell Gross



Back